Zero Cow Factory

Zero Cow Factory emerged to address the environmental and ethical challenges of traditional dairy farming. The company leverages bioengineered microbes to replicate dairy proteins molecularly identical to those from cows, eliminating livestock from the production chain. They produces nature identical dairy proteins primarily A2 beta-casein without animal involvement. The startup has gained traction through partnerships with global accelerators like Mylkcubator (Spain) and Plug and Play (US).

Core Products and Services

• A2 Beta-Casein Protein: World’s first animal-free A2 milk protein, used to formulate cheese, yogurt, ice cream, and supplements.

• Precision Fermentation Technology: Patented process using yeast/microbes to produce dairy-identical proteins (casein, whey) without animals.

• B2B Ingredient Supply: Proteins sold to CPG, dairy, and nutraceutical companies as sustainable raw materials.

Business Model & Revenue Streams

Revenue Model

• B2B Ingredient Sales: Primary revenue from selling proteins to manufacturers (e.g., Fortune 500 CPG firms).
• Licensing Opportunities: Future potential for tech/IP licensing in precision fermentation.
• Geographic Strategy: Initial market entry in US/Singapore (mature regulatory pathways), followed by India.

Customer Segmentation

• Enterprise Clients: Large CPG, dairy and nutraceutical companies (100% B2B focus).

Top Clients & Partnerships

• Pascual Innoventures: Strategic investor and development partner for global dairy alternatives.

• Fortune 500 CPG Companies: Active discussions with top-tier firms for protein supply agreements (confidential).

• Green Frontier Capital/GVFL: Lead investors providing scaling capital and sector expertise.

• Global Accelerators: Mylkcubator (Spain), MassChallenge (Switzerland), Plug and Play (US) for R&D support. Risk Mitigation: Diversified partner pipeline across geographies and sectors minimizes client concentration.

Future Outlook & Strategic Priorities

• Pilot Facility: Scaling production in Gujarat (2024) for commercial launch.

• Regulatory Approvals: Targeting GRAS (US) and novel food certifications (Singapore/India).

• Product Expansion: Developing animal-free whey and lactoferrin. Risks:

• Regulatory Delays: Novel food approvals in India remain uncertain.